首页> 外文期刊>Annals of hematology >Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly
【24h】

Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly

机译:在非霍奇金淋巴瘤患者中加入佩格菲尔玻璃素患者的佩格菲尔克福植物添加到佩格菲尔克福植物中

获取原文
获取原文并翻译 | 示例
       

摘要

Filgrastim is usually combined with chemotherapy to mobilize hematopoietic progenitor cells in non-Hodgkin lymphoma (NHL) patients. Limited information is available on the efficacy of a preemptive plerixafor (PLER) injection in poor mobilizers after chemotherapy and pegfilgrastim. In this prospective study, 72 patients with NHL received chemotherapy plus pegfilgrastim, and 25 hard-to-mobilize patients received also PLER. The usefulness and efficacy of our previously developed algorithm for PLER use in pegfilgrastim-containing mobilization regimen were evaluated as well as the graft cellular composition, hematological recovery, and outcome after autologous stem cell transplantation (auto-SCT) according to the PLER use. A median 3.4-fold increase in blood CD34(+) cell counts was achieved after the first PLER dose. The minimum collection target was achieved in the first mobilization attempt in 66/72 patients (92%) and 68 patients (94%) proceeded to auto-SCT. An algorithm for PLER use was fulfilled in 76% of the poor mobilizers. Absolute numbers of T-lymphocytes and NK cells were significantly higher in the PLER group, whereas the number of CD34(+) cells collected was significantly lower. Early neutrophil engraftment was slower in the PLER group, otherwise hematological recovery was comparable within 12 months from auto-SCT. No difference was observed in survival according to the PLER use. Chemotherapy plus pegfilgrastim combined with preemptive PLER injection is an effective and convenient approach to minimize collection failures in NHL patients intended for auto-SCT. A significant effect of PLER on the graft cellular composition was observed, but no difference in outcome after auto-SCT was detected.
机译:菲拉特通常与化疗相结合,从非霍奇金淋巴瘤(NHL)患者中动员造血祖细胞。在化疗和Pegfilgrastim后,有限的信息可用于Pureplige Plerixafor(Pler)注射在贫困手中的疗效。在这项前瞻性研究中,72名NHL患者接受化疗加上PEGFILGRASTIM,25名难以动员的患者接受过PLER。根据PLET使用,评估我们先前开发的含PEGFILGRETIM的动员方案的PEGFILGRETIM的动员方案中的PEGFILGRETIM的动员方案的含PLERMET的含量的施用算法的有用性和疗效和疗效。在第一钳剂量之后实现了血液CD34(+)细胞计数的中位数3.4倍。在66/72名患者(92%)和68名患者(94%)之前,在第一次动员尝试中实现了最低收集目标。用于Pler使用的算法以76%的贫困流动器满足。 Pler组中T淋巴细胞和NK细胞的绝对数显着较高,而收集的CD34(+)细胞的数量显着降低。早期中性粒细胞植入在PLER组中较慢,否则血液恢复在自动SCT的12个月内相当。根据Pler使用,在存活中没有观察到差异。化疗加上PEGFILGRASTIM联合先发制人的Pler注射,是一种有效且方便的方法,以最大限度地减少用于自动SCT的NHL患者的收集失败。观察到Pler对移植细胞组合物的显着效果,但检测到自动SCT后的结果差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号